Skip to search formSkip to main contentSkip to account menu

BBI608

Known as: BB608, BBI-608 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Purpose: Napabucasin (2-acetylfuro-1,4-naphthoquinone or BBI-608) is a small molecule currently being clinically evaluated in… 
Review
2017
Review
2017
Wnt/β‐catenin pathway is one of the main/frequent dysregulated pathways in several tumor types, including colon cancer. Aberrant… 
2017
2017
TPS3619Background: Cancer stem cells are considered to be fundamentally important for resistance to therapy, recurrence and… 
Review
2017
Review
2017
Napabucasin (BBI608) is an orally administered small molecule that blocks stem cell activity in cancer cells by targeting the… 
2017
2017
3529Background: Cancer stem cells are considered to be fundamentally important for resistance, recurrence and metastasis… 
2017
2017
In colorectal cancer (CRC), cancer stem cells (CSCs) have been hypothesized to mediate cell survival and chemoresistance… 
Highly Cited
2015
Highly Cited
2015
Significance Current cancer treatments ultimately fail owing to metastasis and relapse. The discovery of therapeutic approaches… 
2015
2015
TPS4139 Background: BBI608 is an orally-administered first-in-class cancer stemness inhibitor. By targeting Stat3, BBI608 blocks… 
2015
2015
4069 Background: BBI608, a first-in-class CSC inhibitor that works through inhibiting Stat3, has shown potent synergistic anti…